Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rua BioscienceNZSE:RUA -5.71% Days Payable is 174.30 as of Dec. 2025, which is 63% below its 10-year median of 471.19. The stock has 4 warning signs investors should review. Among 927 Drug Manufacturers companies, Rua Bioscience ranks better than 83.39% on this metric.
The historical rank and industry rank for Rua Bioscience's Days Payable or its related term are showing as below:
NZSE:RUA'
s Days Payable Range Over the Past 10 Years
Min: 191.17 Med: 471.19 Max: 1146.33
Current: 191.17
During the past 5 years, Rua Bioscience's highest Days Payable was 1146.33. The lowest was 191.17. And the median was 471.19.
NZSE:RUA's Days Payable is ranked better than 83.39% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs NZSE:RUA: 191.17
Rua Bioscience's Days Payable
increased
from Dec. 2024 (165.45) to Dec. 2025 (174.30).
It may suggest that Rua Biosciencedelayed paying its suppliers.
Rua Bioscience Days Payable Related Terms
Rua Bioscience Days Payable Historical Data
* Premium members only.
The historical data trend for Rua Bioscience's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:RUA vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rua Bioscience's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rua Bioscience Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rua Bioscience's Days Payable distribution charts can be found below:
* The bar in red indicates where Rua Bioscience's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Rua Bioscience's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rua Bioscience (NZSE:RUA) has a Days Payable of 174.30 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rua Bioscience and its competitors. This is 63% below median its historical median of 471.19. Over the past decade, Rua Bioscience's Days Payable has ranged from 191.17 to 1,146.33. According to the industry distribution chart, Rua Bioscience ranks #154 out of 927 companies in the Drug Manufacturers industry, placing it in the top 16.6%.
Is Rua Bioscience's Days Payable too high?
Rua Bioscience's current Days Payable of 174.30 is 63% below median its 10-year median of 471.19. Over the past 10 years, this metric has ranged from a low of 191.17 to a high of 1,146.33. The Drug Manufacturers industry median Days Payable is 90.38. Rua Bioscience's value of 174.30 is 92.9% above this industry median. Based on the distribution chart, Rua Bioscience ranks #154 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Rua Bioscience's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rua Bioscience ranks #154 out of 927 companies for Days Payable. This places Rua Bioscience in the top 17% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Rua Bioscience's value of 174.30 is 92.9% above this benchmark. Historically, Rua Bioscience's own Days Payable has ranged from 191.17 to 1,146.33 over the past decade. While the company's 10-year median is 471.19 vs. the industry median of 90.38, Rua Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rua Bioscience's current Days Payable of 174.30 is 92.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rua Bioscience and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rua Bioscience's current Days Payable is 174.30, which is 63% below median its own 10-year median of 471.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rua Bioscience stock overvalued right now?
Rua Bioscience (NZSE:RUA) has a current Days Payable of 174.30. The current Days Payable is 174.30, which is 63% below median its 10-year median of 471.19 and 92.9% above the Drug Manufacturers industry median of 90.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Rua Bioscience (NZSE:RUA), the current Days Payable is 174.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rua Bioscience Ltd is a pharmaceutical company engaged in the production of cannabinoid medicines. The company caters to both domestic and international customers. It operates in one segment, being research and development and the sale of pharmaceutical products in Australia, Germany, and New Zealand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:RUA has been successfully added to your 
